WO2001074298A3 - Methods and compositions for regulating memory consolidation - Google Patents

Methods and compositions for regulating memory consolidation Download PDF

Info

Publication number
WO2001074298A3
WO2001074298A3 PCT/US2001/010661 US0110661W WO0174298A3 WO 2001074298 A3 WO2001074298 A3 WO 2001074298A3 US 0110661 W US0110661 W US 0110661W WO 0174298 A3 WO0174298 A3 WO 0174298A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
memory consolidation
compositions
methods
ltm
Prior art date
Application number
PCT/US2001/010661
Other languages
French (fr)
Other versions
WO2001074298A2 (en
Inventor
Cristina M Alberini
Mark F Bear
Original Assignee
Brown University Reseach Found
Hughes Howard Med Inst
Cristina M Alberini
Mark F Bear
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Reseach Found, Hughes Howard Med Inst, Cristina M Alberini, Mark F Bear filed Critical Brown University Reseach Found
Priority to JP2001572044A priority Critical patent/JP2004508288A/en
Priority to AU2001251242A priority patent/AU2001251242A1/en
Priority to EP01924598A priority patent/EP1331930A2/en
Publication of WO2001074298A2 publication Critical patent/WO2001074298A2/en
Priority to US10/251,661 priority patent/US20030166555A1/en
Publication of WO2001074298A3 publication Critical patent/WO2001074298A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention is based on discovery of genes that are up- or down-regulated in inhibitory avoidance, e.g., long-term memory, which genes are therefor believed to have roles in memory consolidation. In particular, we have discovered that memory consolidation involves the regulation of expression of such genes as zif268 (EGR1), insulin-like growth factor (IGF-1), glutamate receptor (1 (GluR1), glutamate receptor 2 (GluR2), c/EBPβ and VGF. For ease of reading, these genes are collectively referred to herein as 'LTM genes', and their encoded proteins as 'LTM proteins'.
PCT/US2001/010661 2000-03-31 2001-04-02 Methods and compositions for regulating memory consolidation WO2001074298A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001572044A JP2004508288A (en) 2000-03-31 2001-04-02 Methods and compositions for adjusting memory consolidation
AU2001251242A AU2001251242A1 (en) 2000-03-31 2001-04-02 Methods and compositions for regulating memory consolidation
EP01924598A EP1331930A2 (en) 2000-03-31 2001-04-02 Methods and compositions for regulating memory consolidation
US10/251,661 US20030166555A1 (en) 2001-04-02 2002-09-20 Methods and compositions for regulating memory consolidation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19361400P 2000-03-31 2000-03-31
US60/193,614 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001074298A2 WO2001074298A2 (en) 2001-10-11
WO2001074298A3 true WO2001074298A3 (en) 2003-05-22

Family

ID=22714335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010661 WO2001074298A2 (en) 2000-03-31 2001-04-02 Methods and compositions for regulating memory consolidation

Country Status (4)

Country Link
EP (1) EP1331930A2 (en)
JP (1) JP2004508288A (en)
AU (1) AU2001251242A1 (en)
WO (1) WO2001074298A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689557B1 (en) * 1994-10-07 2004-02-10 Cold Spring Harbor Laboratory Method of identifying a substance that affects long term memory and CREM/CREB/ATF-1 subfamily members
WO2002052042A2 (en) * 2000-12-22 2002-07-04 Medical Research Council Method for assaying compounds
AU2003202489A1 (en) * 2002-01-10 2003-07-30 Takeda Chemical Industries, Ltd. Screening method
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
US20060040338A1 (en) * 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015190B1 (en) * 1996-06-03 2006-03-21 The Trustees Of Columbia University In The City Of New York Method for enhancing long-term memory in a subject and uses thereof
WO2001068137A2 (en) * 2000-03-14 2001-09-20 Brown University Research Foundation Compositions for regulating memory consolidation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNABEU R. ET AL.: "Involvement of hippocampal AMPA glutamate receptor changes and the cAMP/protein kinase A/CREB-P signaling pathway in memory consolidation of an avoidance task in rats", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 30, 1997, pages 961 - 965, XP002959314 *
ROMANO A. ET AL.: "Acute administration of a permeant analog of cAMP and a phosphodiesterase inhibitor improve long term habituation in the crab chasmagnathus", BEHAVIOURAL BRAIN RESEARCH, vol. 75, 1996, pages 119 - 125, XP002959315 *
See also references of EP1331930A4 *

Also Published As

Publication number Publication date
AU2001251242A1 (en) 2001-10-15
JP2004508288A (en) 2004-03-18
EP1331930A4 (en) 2003-08-06
WO2001074298A2 (en) 2001-10-11
EP1331930A2 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
Gibson et al. Identification of the leucine-rich amelogenin peptide (LRAP) as the translation product of an alternatively spliced transcript
Brownell et al. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation
Takahashi et al. Primary structure of human plasma glutathione peroxidase deduced from eDNA sequences
Shen et al. Hormone response complex in a novel abscisic acid and cycloheximide-inducible barley gene.
Poole et al. The engrailed locus of Drosophila: structural analysis of an embryonic transcript
KR940018464A (en) Method of constructing CDNA library and new polypeptide and DNA encoding it
Kerr et al. The human bone sialoprotein gene (IBSP): genomic localization and characterization
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
KR930702521A (en) Method for obtaining efficient genetic inhibitor and its use
WO1999006549A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
WO1994019465A2 (en) NOVEL DNA- BINDING REGULATOR OF c-myc EXPRESSION WHICH BINDS TO THE FAR UPSTREAM ELEMENTS (FUSE) AND cDNA THEREFOR
WO2001074298A3 (en) Methods and compositions for regulating memory consolidation
KARIMPOUR et al. Sequence of the gene encoding the mitochondrial capsule selenoprotein of mouse sperm: identification of three in-phase TGA selenocysteine codons
IL154102A0 (en) Urocortin proteins and uses thereof
Wolfraim et al. Cloning and sequencing of the cDNA for cas17, a cold acclimation-specific gene of alfalfa.
WO1999001551A3 (en) Novel inhibitor of cellular proliferation
Orozco et al. Cloning of the gene and complete cDNA encoding a type 2 deiodinase from Fundulus heteroclitus
Ninkina et al. Rat and chicken s-rex/NSP mRNA: nucleotide sequence of main transcripts and expression of splice variants in rat tissues
Johansen et al. Sequence, conservation, and quantitative expression of rainbow trout Myf5
WO2006015045A3 (en) Methods and compositions for modulating flowering and maturity in plants
Lewis et al. The sequence of the Kluyveromyces lactis BiP gene.
WO2000009712A8 (en) Transcription factors regulating the expression of ethylene-inducible genes
Ray et al. Rabbit serum amyloid a gene: Cloning, characterization and sequence analysis
EP1007677B1 (en) Protease-related protein
WO2001055298A3 (en) Use of a nucleotide sequence for enhancing protein synthesis and expression of proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572044

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001924598

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001924598

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001924598

Country of ref document: EP